Phase 1 Trial of the Plasmodium falciparum Blood Stage Vaccine MSP1 42 -C1/Alhydrogel with and without CPG 7909 in Malaria Naïve Adults

Ruth D. Ellis, Laura B. Martin, Donna Shaffer et al. · 2010

Read Phase 1 Trial of the Plasmodium falciparum Blood Stage Vaccine MSP1 42 -C1/Alhydrogel with and without CPG 7909 in Malaria Naïve Adults by Ruth D. Ellis, Laura B. Martin, Donna Shaffer et al. (2010) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/plos-pone-0008787.txt.

Description

Ruth Ellis, Laura Martin, Donna Shaffer, and colleagues ran an early safety trial of a malaria vaccine. Their phase 1 report appeared in PLOS ONE in 2010. The vaccine targets MSP1, a protein on the blood-stage parasite. Two versions of the protein were mixed to cover its common variants. Volunteers had never had malaria, giving a clean readout. An added booster ingredient, CPG 7909, was tested in one arm.

Adults received the vaccine with or without the booster. The team tracked side effects and antibody responses. Phase 1 success means the vaccine can move to trials where malaria circulates. Malaria still kills hundreds of thousands yearly.

Catalog record

CREATORRuth D. Ellis, Laura B. Martin, Donna Shaffer et al.
YEAR2010
COLLECTIONPAPERS
FORMATTXT
FILE SIZE45 KB
LICENSECreative Commons CC0 License
RIGHTSCC0
SOURCEPLOS ONE

Source: https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0008787

Browse the full library · About the Tower of Babel